vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and FIRST COMMONWEALTH FINANCIAL CORP (FCF). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $133.7M, roughly 1.5× FIRST COMMONWEALTH FINANCIAL CORP). FIRST COMMONWEALTH FINANCIAL CORP runs the higher net margin — 28.1% vs -14.6%, a 42.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 13.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 5.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
AXSM vs FCF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $133.7M |
| Net Profit | $-28.6M | $37.5M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 28.1% |
| Revenue YoY | 65.0% | 13.0% |
| Net Profit YoY | 61.9% | 14.8% |
| EPS (diluted) | $-0.55 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $133.7M | ||
| Q4 25 | $196.0M | $137.9M | ||
| Q3 25 | $171.0M | $136.0M | ||
| Q2 25 | $150.0M | $131.0M | ||
| Q1 25 | $121.5M | $118.0M | ||
| Q4 24 | $118.8M | $120.4M | ||
| Q3 24 | $104.8M | $121.2M | ||
| Q2 24 | $87.2M | $120.2M |
| Q1 26 | — | $37.5M | ||
| Q4 25 | $-28.6M | $44.9M | ||
| Q3 25 | $-47.2M | $41.3M | ||
| Q2 25 | $-48.0M | $33.4M | ||
| Q1 25 | $-59.4M | $32.7M | ||
| Q4 24 | $-74.9M | $35.8M | ||
| Q3 24 | $-64.6M | $32.1M | ||
| Q2 24 | $-79.3M | $37.1M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 40.9% | ||
| Q3 25 | -27.0% | 38.1% | ||
| Q2 25 | -24.5% | 32.1% | ||
| Q1 25 | -46.9% | 34.8% | ||
| Q4 24 | -61.1% | 37.1% | ||
| Q3 24 | -59.8% | 33.4% | ||
| Q2 24 | -89.5% | 38.7% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | -14.6% | 32.5% | ||
| Q3 25 | -27.6% | 30.4% | ||
| Q2 25 | -32.0% | 25.5% | ||
| Q1 25 | -48.9% | 27.7% | ||
| Q4 24 | -63.1% | 29.8% | ||
| Q3 24 | -61.7% | 26.5% | ||
| Q2 24 | -91.0% | 30.9% |
| Q1 26 | — | $0.37 | ||
| Q4 25 | $-0.55 | $0.44 | ||
| Q3 25 | $-0.94 | $0.39 | ||
| Q2 25 | $-0.97 | $0.32 | ||
| Q1 25 | $-1.22 | $0.32 | ||
| Q4 24 | $-1.54 | $0.35 | ||
| Q3 24 | $-1.34 | $0.31 | ||
| Q2 24 | $-1.67 | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | $154.9M |
| Stockholders' EquityBook value | $88.3M | $1.6B |
| Total Assets | $689.8M | $12.3B |
| Debt / EquityLower = less leverage | — | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | — | $154.9M | ||
| Q4 25 | — | $261.7M | ||
| Q3 25 | — | $262.1M | ||
| Q2 25 | — | $262.4M | ||
| Q1 25 | — | $262.7M | ||
| Q4 24 | — | $263.0M | ||
| Q3 24 | — | $136.3M | ||
| Q2 24 | — | $136.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $88.3M | $1.6B | ||
| Q3 25 | $73.7M | $1.5B | ||
| Q2 25 | $73.1M | $1.5B | ||
| Q1 25 | $53.2M | $1.4B | ||
| Q4 24 | $57.0M | $1.4B | ||
| Q3 24 | $92.9M | $1.4B | ||
| Q2 24 | $102.9M | $1.4B |
| Q1 26 | — | $12.3B | ||
| Q4 25 | $689.8M | $12.3B | ||
| Q3 25 | $669.3M | $12.3B | ||
| Q2 25 | $639.8M | $12.2B | ||
| Q1 25 | $596.7M | $11.8B | ||
| Q4 24 | $568.5M | $11.6B | ||
| Q3 24 | $561.5M | $12.0B | ||
| Q2 24 | $548.2M | $11.6B |
| Q1 26 | — | 0.10× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $187.5M | ||
| Q3 25 | $1.0M | $49.5M | ||
| Q2 25 | $-32.4M | $30.4M | ||
| Q1 25 | $-43.4M | $55.9M | ||
| Q4 24 | $-26.2M | $129.5M | ||
| Q3 24 | $-18.6M | $53.6M | ||
| Q2 24 | $-30.1M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $171.5M | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | $113.9M | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 124.3% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | 94.6% | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 11.7% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | 12.9% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.18× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 1.71× | ||
| Q4 24 | — | 3.61× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
